Active Biotech has announced the completion of patient enrolment for Phase II clinical trials for TASQ, a novel compound for the treatment of prostate cancer.
The company will conduct a 2:1 randomised, placebo-controlled, double-blind Phase II study using 1mg/day of TASQ against a placebo.
The object of the study is to measure the proportion of patients that do not display disease progression after six months of TASQ therapy.
Secondary objectives include measuring time to clinical progression, safety and changes in prostate specific antigen blood levels.
Results from this study are expected by the end of 2009 or beginning of 2010.